NEW YORK (Jan. 29, 2008) -- The Prostate Cancer Foundation, largely through the generosity of David H. Koch, has given $5 million to four institutions, including Weill Cornell Medical College, to support novel research in prostate cancer. The gift is one of the largest-ever individual donations for prostate cancer research.
The multidisciplinary research team, created by the Prostate Cancer Foundation, will seek to develop a novel nanomedicine for prostate cancer that can be given intravenously and delivered directly to targeted sites of prostate cancer. Nanomedicine is the application of nanotechnology -- engineering compounds or machines on a molecular or atomic scale -- to the prevention and treatment of disease.
At Weill Cornell, the research effort will be led by Dr. Neil Bander, a physician-researcher who heads one of the world's most experienced and accomplished teams in antibody-targeted therapy in urological cancers.
"We are very grateful to Michael Milken and Dr. Jonathan Simons of the Prostate Cancer Foundation and David Koch for their foresight and generosity in supporting a multi-institutional collaboration that brings together leaders in their respective fields with the goal of creating a synergy that will lead to significant benefit for cancer patients. I think we all agree that this is the model required to create complex solutions to solve complex problems," says Dr. Bander, director of urological oncology research and the Bernard and Josephine Chaus Professor of Urological Oncology at Weill Cornell Medical College and a urologist at NewYork-Presbyterian Hospital/Weill Cornell Medical College.
Several years ago, Dr. Bander's team developed the first antibodies to the external domain of prostate-specific membrane antigen (PSMA). PSMA is now widely considered the best prostate cancer cell surface target known. The lead antibody, J591, has been a focus of clinical trials at Weill Cornell, involving the Departmen
|Contact: Andrew Klein|
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College